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Abstract
Background: Recruitment to randomised controlled trials (RCTs) is challenging. Pre-trial qualitative research
provides insights into the feasibility and acceptability of proposed trial designs and delivery; however, this is rarely
conducted. This paper reports on work undertaken in advance of the Prepare for Kidney Care trial (formerly
PrepareME), which compares preparing for dialysis with preparing for conservative care for patients with chronic
kidney disease. The paper describes how the findings refined plans for the forthcoming trial.
Methods: Semi-structured interviews were undertaken with health-care professionals involved in delivering or
recruiting to the trial. Interview findings were considered in relation to observations of a patient advisory group
workshop and introductory site visits, which were set up to present the trial to professionals involved in the internal
pilot phase of the RCT. The use of findings and input from multiple sources was intended to support suggested
refinements to the forthcoming trial. The findings were fed back to the trial management group and other expert
stakeholders.
Results: Sixteen health-care professionals were interviewed, and one patient advisory group workshop and six
introductory visits to sites involved in the internal pilot were observed. The professionals interviewed included renal
consultants, nurses and renal social workers. Key themes identified from the interviews, supported by the
observations, were concerns around the eligibility criteria, the feasibility of the trial intervention, imbalances in the
presentation of the trial arms, and anticipated recruitment issues arising from patients’ and clinicians’ preferences
for one arm or the other. Changes to the design were made in response, including to the content of the
intervention, the presentation of the trial arms and the name of the RCT.
Conclusions: This study highlights the value of carrying out pre-trial work with health-care professionals to identify
issues with delivering the proposed trial. This work can be particularly valuable in trials of new interventions, for
which the barriers to their integration into routine care are unknown. This work has important implications for
facilitating the identification of further obstacles in the main RCT. We suggest that pre-trial qualitative work is
undertaken to address design issues early on, in addition to ongoing qualitative research to monitor the
emergence of obstacles affecting recruitment.
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Background
Recruitment to randomised controlled trials (RCTs) is
challenging, with only 56% of publicly funded RCTs in
the UK reaching recruitment targets [1]. The reasons for
recruitment failure often relate to issues around trial
design and delivery, including logistical problems and
equipoise issues relating to the trial arms [2, 3]. Briel
and colleagues suggested that 89% of obstacles leading
to the discontinuation of RCTs could be avoided if issues
were identified and addressed during the trial planning
stages [3]. Patient and public involvement (PPI) at the
design stage has been reported as having a positive im-
pact on RCT recruitment through, for example, suggest-
ing ways to make the trial more attractive to potential
participants [4]. Several studies have also highlighted the
benefits of undertaking qualitative research at the
pre-trial phase, with a view to refining study design and
exploring the acceptability and feasibility of carrying out
proposed trial processes [5, 6]. O’Cathain and colleagues
[5] noted, however, that very little of this type of
pre-trial research is undertaken, despite its potential to
optimise trial design and recruitment. This particularly
applies to research with health-care staff involved in de-
livery and recruitment to RCTs [7].
This article reports on pre-trial qualitative work carried
out in advance of recruitment to the Prepare for Kidney
Care RCT. Originally, and at the time of undertaking this
qualitative research, the RCT was named PrepareME, and
was set up in response to uncertainty around the survival
and health-related quality of life benefits associated with
different approaches to managing end-stage chronic kid-
ney disease in patients aged 80 years and over, and those
aged 65 years and over with other comorbidities [8]. A
preceding UK-based mixed-methods study showed great
variability in how these patients were being treated in Na-
tional Health Service (NHS) hospitals around the country,
in terms of whether they prepared for (and started) dialy-
sis or conservative care [9]. Given these uncertainties, the
trial aimed to investigate the relative clinical and cost-ef-
fectiveness of preparing patients for dialysis versus prepar-
ing them for conservative care [8].
The aim of this qualitative pre-trial work was to
explore the acceptability and feasibility of conducting
the PrepareME trial from the perspective of the clinical
professionals who would be delivering it. This was with
a view to refining the presentation of the RCT and the
protocol to optimise recruitment and retention, and
particularly, to identify barriers to integrating the trial
into routine care.
Trial context
Patients eligible for inclusion in PrepareME needed to
have existing or newly diagnosed stage 5 chronic kidney
disease (CKD), with an estimated glomerular filtration
rate (eGFR) (i.e. kidney function) of <15 mL per min per
1. 73 m2. Patients also needed to be either 80 years of
age or over, or 65 years of age and over with other health
comorbidities (Table 1).
The original trial arms compared in the PrepareME
RCT were Prepare for dialysis and Prepare for conservative
care (Fig. 1). The Prepare for dialysis arm was described as
standard care, referring to usual practice in the recruiting
site (most likely including surgery for dialysis access, deci-
sions regarding patients’ preferred dialysis modality and
regular hospital clinic visits). Prepare for conservative care
was a newly proposed treatment pathway, developed spe-
cifically for the trial because previous research had found
variation in the content and delivery of conservative care
pathways across UK NHS renal units [9]. The intervention
consisted of three phases:
 Assess and launch entailed evaluating patients’ needs
through advanced CKD assessments and developing
a plan of action to meet these.
 Maintain involved implementing the plan of action
whilst continuing to review and respond to
symptoms.
 Support enhancement focused on delivering end-of-
life care to patients, including relieving pain and
symptoms and advanced-care planning.
A key element of Prepare for conservative care was the
delivery of care within patients’ homes, aimed at support-
ing patients whilst reducing the number of hospital visits.
Sites were required to offer up to three home visits to
Table 1 PrepareME eligibility criteria: inclusion criteria
PrepareME patient eligibility criteria
Patients known to renal services with new or existing stage 5 CKD
(eGFR <15, with at least one result confirming this in the last 12
months) and
- Aged 65+ with a World Health Organisation (WHO) performance
status 3+, or
- Aged 65+ with a Davies co-morbidity score 2+, or
- Aged 80+.
WHO performance status classification: 0 = Fully active, able to carry out
all normal activities without restriction;
1 = Restricted in physically strenuous activity but ambulatory and able
to carry out work of a light or sedentary nature; 2 = Ambulatory and
capable of all self-care but unable to carry out any work activities; up
and about more than 50% of waking hours; 3 = Symptomatic and in
a chair or in bed for greater than 50% of the day but not bedridden;
4 = Completely disabled; cannot carry out any self-care; totally confined
to bed or chair.
Davies co-morbidity score: Each of the following scores one point: Ma-
lignancy, ischaemic heart
disease, peripheral vascular disease (including stroke), left ventricular
dysfunction, diabetes mellitus, systemic collagen vascular disease,
other significant pathology (including COPD, cirrhosis, psychiatric
illness or HIV).
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease,
eGFR estimated glomerular filtration rate, HIV human immunodeficiency virus,
WHO world health organisation
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patients within the first 12 weeks of allocation as part of
the assess and launch phase. The maintain phase con-
sisted of intermittent home and hospital clinic visits, with
monthly telephone contact from a health-care
professional. The support enhancement phase was
designed to include up to three home visits (Fig. 1).
Recruitment was designed to be led by research nurses,
but multiple health-care professionals could be involved,
including clinical care nurses, renal consultants and renal
social workers. A summary of the intended recruitment
pathway—from identification of patients to obtaining writ-
ten consent—is shown in Fig. 2. A research nurse (or an-
other health-care professional) was required to identify
potentially eligible trial participants, with eligibility being
confirmed by a renal consultant. Renal consultants would
initially approach eligible patients about trial participation,
by providing a brief verbal summary of the study, and a
short invitation letter and introductory patient informa-
tion sheet. A research nurse (or other health-care profes-
sional) then contacted the patient by telephone to see if
they were interested in receiving a home visit to discuss
the study. Up to three home visits to provide informa-
tion about the RCT were permitted. Conducting these
recruitment discussions at home, rather than in clinic,
was a suggestion made by PPI co-applicants prior to
the trial, who felt that this would make it easier for
friends, family and carers to be involved in making
the decision about trial participation.
Fig. 1 The PrepareME trial pathways
Fig. 2 The PrepareME patient recruitment pathway. RCT randomised
controlled trial
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An internal pilot phase was built into the trial for the
first year of recruitment, which involved the RCT being
implemented in a subset of centres, to pilot the logistics
and identify barriers to delivering the trial prior to the
main study [10]. A follow-up cohort study using the UK
renal registry was also set up alongside the RCT to
capture observational follow-up outcome data for
patients who declined to participate in the RCT.
Methods
Study design
This was a qualitative research study, consisting of
semi-structured interviews with health-care professionals.
The qualitative research also drew upon observations of the
PrepareME patient advisory group (PAG) workshop and
introductory site visits. Ethical approval for the qualitative
study was obtained from the research ethics committee of
the Faculty of Health Sciences at the University of Bristol
(reference 44001).
Semi-structured interviews
Sampling and recruitment
A purposive sampling strategy was adopted to target
professionals who were delivering existing renal care and
treatment to the eligible patient population, and those
who were anticipated to influence the recruitment and
retention of patients (i.e. assessing patients for eligibility,
introducing trial participation to patients and delivering
patient care as required by the RCT arms). Sampling
aimed to achieve wide variation by capturing individuals
in different clinical roles across all six sites involved in
the internal pilot phase of the RCT [11, 12]. Sites were
spread across various regions in England and were
selected for the internal pilot phase because the trial
team knew that they were offering different models of
conservative care to patients. Participants for the inter-
views were identified through introductory site visits and
existing links with the chief investigator (CI) and the
trial management group (TMG). Snowball sampling was
also employed, in which participants were asked to
suggest other individuals who may have a role in
delivering the trial in their centres [13].
Interviews were undertaken in waves to allow subse-
quent sampling to be guided by previous data collection
and with the intention to develop themes [14]. Staff were
invited to take part in an interview via email and were sent
a study information sheet. Those who agreed to take part
were asked to suggest a convenient date and time for the
interview. Attempts were made to organise the interviews
after staff had received their introductory site visit and had
had the study explained to them by the CI, to allow them
time to absorb and understand the protocol. Those who
did not respond were sent a reminder by email 2 weeks
after the initial contact.
Data collection
Semi-structured interviews were conducted by SH
between February 2017 and March 2017, either face to
face or over the telephone. SH is a qualitative researcher
by background, with a PhD in social sciences. She had no
prior relationship with the health-care staff approached
for interview and was not involved in the early develop-
ment of the trial design. A flexible topic guide was
developed from previous studies. For instance, questions
relating to equipoise and the trial eligibility criteria were
informed by the previous integration of the Quintet Re-
cruitment Intervention (QRI) into trials, since these issues
have been commonly explored in the early stages of RCTs
[15, 16]. Other questions covered details about how pa-
tients are managed in routine clinical practice, partici-
pants’ perceived acceptability and the relevance of the
study design and intervention, and views on the feasibility
of trial conduct (especially recruitment). The topic guide
was also reviewed with other researchers who had prior
experience of conducting research with renal profes-
sionals. We did not pilot the topic guide, but we added
further prompts, probes and questions as data collec-
tion proceeded.
Interviews continued until data saturation occurred,
determined to be the point at which no new issues were
being introduced by new participants, and the views
within the key themes identified (i.e. those with implica-
tions for trial design and delivery, as reported in this
paper) were being replicated across different health-care
professionals from different backgrounds and contexts
[17]. Interviews were audio-recorded after the partici-
pant had provided written informed consent and they
were transcribed verbatim. The mean length of an inter-
view was 44min (ranging from 27 to 69min).
Data analysis
Transcripts were checked against audio-recordings for
accuracy and imported into NVivo 10 for coding. Inter-
views were analysed using methods of constant compari-
son, which require new data to be continually compared
with existing data to enhance understanding and explore
relationships between themes [14]. Interview data were
coded line by line. Themes were initiated and evolved
through the continual comparison of data. Interviews
were undertaken in batches of two or three so that exist-
ing findings could inform subsequent data collection, and
the coding structure could be updated to encompass new
themes. A descriptive account was generated to summarise
themes and set out similarities and differences between
participants’ perspectives. Analysis was undertaken by two
experienced qualitative researchers, primarily by SH, with
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10% of transcripts coded independently by LR to promote
reliability [18]. SH and LR met regularly to discuss the find-
ings and to ensure that they agreed on the overarching is-
sues emerging from the interviews [19]. Conversations
focused on whether adaptations should be made to the
overall coding strategy to ensure that no important themes
were being missed. Findings from the interviews were sum-
marised in a report for the CI and then presented to
broader trial stakeholders at an expert consensus meeting,
with the aim of finalising trial details and refining the study
protocol. This meeting took place on 17 March 2017 and
was attended by individuals involved in study oversight
(TMG members), researchers working on the project, study
co-applicants and PPI representatives.
Observations of introductory site visits and the PAG
workshop
Observations of introductory site visits and the PAG work-
shop were undertaken to capture the views of additional
key stakeholders on the trial design. Key issues identified
from observations with further health-care professionals
and patient representatives helped to inform changes to the
interview topic guide, which could be further explored in
subsequent interviews. This was intended to triangulate dif-
ferent sources of information [20] and to explore whether
consistent views were emerging from different stakeholders
and forums (i.e. group versus individual insights). Con-
sidering information from these different sources helps
to confirm emerging insights from any one source (i.e.
strengthening credibility) and build a more comprehensive
understanding of the possible barriers and facilitators to
the successful delivery of the trial. This was important for
presenting a confident rationale for any proposed changes
to the trial design or protocol. In some cases, findings
from the qualitative interviews were fed into the observed
meetings (i.e. the PAG) for discussion.
Introductory site visits
The CI, trial manager and qualitative researcher(s)
conducted introductory site visits at all six renal units in-
volved in the internal pilot phase of the RCT. The visits took
place prior to the RCT, between 9 January and 3 April 2017.
The purpose of these visits was to introduce the details of
the RCT, explore how the trial processes might work in
practice and address any questions or queries. These visits
were attended by clinical and recruitment staff, including
site principal investigators, research nurses, research co-
ordinators, and dialysis and conservative care nurses.
Patient advisory group workshop
A face-to-face PrepareME PAG consisting of PPI represen-
tatives was set up in advance of the trial’s commencement
to obtain feedback on the clarity and presentation of pa-
tient information sheets and questionnaires. Members of
the PAG were given a summary of the proposed RCT at
the beginning of the workshop. The workshop was chaired
by the CI on 7 March 2017 (i.e. after most of the interviews
had been conducted) and lasted approximately 2 hours.
Output from the observations
SH and LR took detailed notes at both the introductory site
visits and the PAG meeting. During the site visits, general
points relating to attendees’ reactions to aspects of the
study and any questions or queries that arose were noted.
In the PAG, general notes about the issues raised during
the discussions were recorded and official written minutes
were taken by the trial manager. Notes and minutes from
site visits and the PAG workshop were collected, and the
key issues identified were compared to those from the
interview data, drawing on techniques of constant compari-
son (as outlined above) [14]. A timeline of data collection
and written and oral presentations of the qualitative re-
search findings is presented in Fig. 3.
Fig. 3 Timeline of qualitative data collection and feedback
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Results
Participants
Sixteen health-care professionals were approached for
the semi-structured interviews, and all agreed to take
part. Interviews involved participants from four of the six
acute NHS trusts participating in the internal pilot phase
of PrepareME. Those interviewed included renal consul-
tants (n = 6), CKD nurses (n = 4), conservative care nurses
(n = 2), palliative care nurses (n = 2) and renal social
workers/counsellors (n = 2). Three of the renal consul-
tants were the principal investigators for the trial, and two
of these were also co-applicants. Interview participant
characteristics, including their anticipated roles in the
RCT, are shown in Table 2. The PAG workshop was
attended by eight PPI representatives, two PPI specialists,
the CI and four other members of the TMG.
Key themes identified from the interviews are presented
below with illustrative quotes throughout. Identifiers (P1–
P16) have been used to protect participant and recruitment
site identities. Themes that were also supported by discus-
sions arising in the PAG and introductory site visits are
indicated. The final part of this section discusses changes
made to the trial design because of the research.
Concerns around the trial eligibility criteria
Clinical criteria
Some participants expressed concerns about the proposed
trial inclusion criteria (Table 1), specifically the need for
patients to have an eGFR of <15. These concerns were dis-
cussed by consultants and nurses across two of the four
recruiting sites and flagged in introductory visits to these
sites (sites 3 and 4). In general, concerns aligned with the
idea that patients have typically already made decisions re-
garding their preferred treatment pathway by the time
their kidney function had declined to this level:
P8: “Less than 15, an eGFR, is quite late. … In reality,
a good few of our patients … would have made their
decision before their eGFR is less than 15, and we
would have been encouraging that.”
Age and health status
Professionals questioned the appropriateness of the age and
health-related criteria, suggesting that particular groups of
eligible patients might be more suited to one treatment
pathway over the other, although views were not shared in
relation to sub-groups of eligible patients. For example, a
quarter of those interviewed (all conservative care nurses or
renal social workers) stated that patients aged 80 and over
would be more suitable for or more likely to opt for conser-
vative care (P9), whilst another quarter of those interviewed
(mostly consultants) suggested it was favourable for pa-
tients aged 80 and over to receive dialysis if they were
deemed to be otherwise healthy (P8):
P9 (palliative care nurse): “Those 80 or over, the
evidence has shown there is very little benefit of having
dialysis and it actually can impact their quality of life.”
P8 (renal consultant): “She’s 85, plays golf twice a
week. … She’s absolutely fit as a flea. … I might be
tempted to weigh my judgement towards dialysis,
because she has such a good quality of life.”
Concerns were also expressed in relation to patients aged
65 and over with comorbidities. Just under half of interview
participants conveyed discomfort with including these
patients in the trial, as they were deemed to be too
young to receive conservative care (irrespective of their
co-morbidities):
P6 (CKD nurse): “It’s a fairly young cut-off. … I think there
are probably many people that are [in the] 65 age group
would recommend the first stage, trying dialysis first.”
However, a few participants, particularly nurses who
delivered conservative care, were of the view that patients
aged 65 with severe comorbidities were more suited to
conservative care:
P3 (conservative care nurse): “65 and then your
comorbidity’s two plus. … I’d probably say they’re the
Table 2 Interview participants’ professional roles and anticipated role in RCT
Professional roles Participant IDs Sites Anticipated role in the trial
Conservative care nurses P1, P3 4 Delivering Prepare for conservative care
Palliative care nurses P2, P9 3 Delivering Prepare for conservative care
Renal consultants P4, P5, P7, P8, P10, P16 3, 4, 6 Identifying patients for the RCT (n = 6)
Trial principal investigator and trial co-applicant (n = 2), co-applicant
(n = 2) or trial principal investigator only (n = 1)
Chronic kidney care nurses P6, P12, P14 1, 3 Delivering Prepare for dialysis
Renal education nurse P11 4 Introducing treatment pathways to patients (prior to the RCT)
Renal social worker/counsellor P13, P15 6 Delivering care or support within Prepare for conservative care
RCT randomised controlled trial
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ones who don’t do so well on dialysis. So, maybe in an
ideal world … they probably would be better for opting
for conservative [care].”
The issues around eligibility emerging from the interviews
tended not to be raised in the introductory site visits.
The trial intervention: Prepare for conservative care
Intervention content
Comments on the intervention focused on the delivery
of the home visits, with most participants supportive
of their value and suggesting that it was useful to
evaluate patients’ care needs within their own home.
Some believed home visits allowed patients ownership
and control:
P1 (conservative care nurse): “You can make an
assessment … how they’re managing on a day-to-day
basis. … Do you need district nurses or a package of
care coming in?”
P9 (palliative care nurse): “People are often more
comfortable talking in their own home. They have a
bit more control.”
Most discussion around the home visits focused on the
cost of delivery, as home visits were considered as excess
treatment costs and therefore, were not covered by the
trial. Professionals commented on the ability of sites to
deliver home visits, with issues raised relating to the time
and money required for staff to undertake additional visits
(over and above those offered in routine practice), both in
terms of how the visits would be funded, and issues
around the availability of staff to deliver these:
P6 (CKD nurse): “We will need to work out how we can
offer [home visits]. I think everybody’s in the same
situation. ... We’re really stretched in terms of resources.”
However, participants from two of the sites (sites 4
and 6), which were delivering home visits regularly as
part of their standard care, appeared more optimistic
about their ability to deliver the intervention:
P15 (renal social worker): “I don’t think [the home
visits] would be a problem. These are patients that are
our patients anyway, so we would be seeing them …
because we do that work anyway.”
Despite general support for integrating home visits into
the Prepare for conservative care pathway, half of those
interviewed expressed that the number of specified home
visits (three) was too intensive, suggesting that this set-up
might not suit the wishes and lifestyle of all patients:
P2 (palliative care nurse): “It may be too much for
some. … You wouldn’t go three times into the home of
someone who didn’t want you in their house and
didn’t need you.”
Hesitations about the volume or frequency of home
visits tended not to be expressed at the introductory site
visits (with one exception, site 5, which suggested that
the number of visits might be problematic in terms of
the resources they had available).
Intervention name
Around a third of participants suggested that the name Pre-
pare for conservative care implied a passive approach to
delivering care, in contrast to active implications of Prepare
for dialysis. As such, participants suggested alternative
names that they felt might mitigate the possibility of
patients misinterpreting what conservative care entailed:
P6 (CKD nurse): “We quite like having ‘maximum’
[conservative management] because it’s … having a
proactive approach to it, isn’t it? … I think there is,
maybe, an element of just emphasising that we are
still doing something although it’s conservative. … I
think … just ‘conservative’ is maybe a bit lacking.”
Observations from the PAG workshop supported this
finding after the CI (chair) asked PPI representatives for
their views on the name of the intervention. This was
not on the original meeting agenda, but the qualitative
team had informally fed back some of the interview
findings to the CI. Several of the attendees suggested
that the term ‘conservative care’ held negative connota-
tions, with implications that patients would be left to die
on this pathway. PPI representatives similarly preferred
the proposed use of more active terms, including the
suggested ‘supportive care’ and ‘active clinical care’.
Balancing the trial pathways
Interview participants commented on the presentation
of the study pathways within the RCT patient infor-
mation sheet, particularly the differences in the
phases of care represented in the study design
(Table 1). An interview participant (P2) suggested that
the lack of portrayal of a palliative care element
within the Prepare for dialysis arm gave the impres-
sion that a patient’s health would not decline if they
were randomised to this pathway:
P2 (palliative care nurse): “Have we got any advanced
care planning built into the preparation for dialysis? I
think it would be really helpful to know what happens
if you were recognised as dying in both arms.”
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Comments from the PAG supported this, as members
observed that only the Prepare for conservative care
pathway appeared to lead to death (as stated in the offi-
cial PAG minutes).
Issues with recruitment to PrepareME
Participants were asked for their views on recruitment to
PrepareME, particularly perceptions of recruitment diffi-
culties. Several potential threats to recruitment arose, some
specifically in the context of compromising recruitment,
whilst others were mentioned without reference to recruit-
ment, but could be seen to complicate or threaten trial par-
ticipation. A few participants commented directly on the
name of the trial, with a consultant (P7) suggesting that it
might have negative connotations for other clinical staff:
P7 (renal consultant): “I’ve had some person refer to it
as the ‘prepare me to die’ study. Seriously.”
A further recruitment barrier identified directly by
those interviewed were patient preferences, with around
half of participants suggesting that eligible patients
would have strong views about their preferred treatment
pathway, and thus may not agree to randomisation:
P8 (renal consultant): “I’m always surprised how fixed
people’s opinions are, and when you do try to explore
them, yes, occasionally you get people to open up their
minds. … But sometimes, it’s almost as if like, they’re
not really listening.”
However, a few professionals stated views to the con-
trary, believing that most patients do not have fixed or
well-informed views:
P16 (renal consultant): “People have read about
dialysis and have decided it’s not for them. But it’s not
always an informed decision. So, even if they say they
don’t want to have dialysis … we wouldn’t necessarily
take that at face value because, in my experience, a lot
of people … change their minds.”
Around a quarter of those interviewed suggested
clinician equipoise would be an issue for other clini-
cians involved in the study, implying that when initially
discussing the trial with potential participants, clinicians
may unintentionally introduce treatment pathways in a
biased way because of their belief that patients might be
more suited to one intervention over the other:
P15 (renal social worker): “[Clinicians] provide unclear
or skewed information to try to encourage someone to go
down the conservative care pathway—not for any
underhand reason but because they do sincerely believe
that for that individual that would be the right route. …
That happens in practice everywhere.”
Potential issues around equipoise were also apparent
in some participants’ suggestions that they would be un-
comfortable randomising patients. Some of these ac-
counts were linked to comments on the registry
follow-up study. Without prompting, a quarter of
participants discussed the value of the registry study,
but some also gave the impression that the registry
could be a good substitute for the RCT:
P5 (renal consultant): “I think that, actually, [the
registry study is] a saviour for me. … If [patients] don’t
want to be randomised they could be followed up.”
Changes to the trial design
Findings from the semi-structured interviews were ana-
lysed and summarised in a report for the CI and later
discussed with trial stakeholders at an expert consensus
meeting (see Fig. 3 for a timeline of events). At this
meeting, the qualitative team presented the key issues
raised by the health-care professionals, using anon-
ymised quotations from the interviews as evidence.
Experts were then given the opportunity to give their
thoughts on these issues, which were recorded in the
official meeting minutes. This included a consensus for
changing the name of the RCT and the name of the Pre-
pare for conservative care arm. In a series of further meet-
ings between the CI, TMG and qualitative team, the
feedback from the expert consensus meeting and the in-
sights from the introductory site visits and the PAG work-
shop were considered and used in support of making
practical changes to the trial design and presentation, and
amendments to the study protocol. These changes are
discussed below.
Changes to the trial arms
The intervention content
Concerns about the practicalities and resource implica-
tions of delivering the home visits were considered and
discussed in depth, with the CI taking an active role in
negotiating local solutions that worked for staff in each
site—a time-consuming but important process that was
not anticipated at the funding acquisition stage. In
response to these issues, and concerns about patients’
potential reluctance to accept frequent home visits, the
CI proposed to amend the protocol by reducing the
number of compulsory home visits in the earliest assess
phase of the pathway. The number of visits was changed
from three to a minimum of one, allowing the final
number to be influenced by the individual requirements
and preferences of each patient.
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The intervention name
The CI and TMG decided to reconsider the name of the
intervention, taking on board interview participants’ and
the PAG members’ suggestions for clarifying the arm’s
active nature of delivering care. ‘Prepare for responsive
management’ was put forward by the qualitative team, fol-
lowing discussions with the CI about what activities the
intervention arm entailed. The term ‘responsive’ was pro-
posed to communicate the responsive nature of monitoring
and reacting to patients’ symptoms in this care pathway.
The term ‘management’ was intended to reflect the active
component of the intervention, which interview partici-
pants and the PAG felt was previously absent. The pro-
posed revised name was approved by the CI, TMG and PPI
representatives.
Presentation of the trial arms
Perceived imbalances between the trial arms were
addressed through changes to how the Prepare for dialysis
pathway was presented. The CI and qualitative research
team worked together to redesign the trial arms, to illus-
trate the balance between the arms and ensure the infor-
mation presented accurately reflected the CI and TMG’s
plans for what the trial arms would involve. These changes
constituted adding an assess phase (formerly absent), and
a supportive care phase (formerly, support enhancement)
to the Prepare for dialysis arm, to mirror the phases pre-
sented in Prepare for conservative care. Detailed
descriptions of activities in each of the phases used the
same terminology for each of the trial arms as far as pos-
sible, with a view to making the similarities and key differ-
ences between the trial arms clear. Figure 4 shows the
revised presentation of the trial arms, and the trial path-
ways before and after the qualitative work are given in
Fig. 5.
Name of the RCT
The CI and TMG felt the name of the RCT should be
revised, in response to some interviewees’ perceptions
that PrepareMe had possible negative connotations. A
change to the trial name was also supported by the re-
search ethics committee (March 2017). Potential alterna-
tives were devised and circulated to the PAG for their
feedback. ‘Prepare for kidney care’ was the option
favoured by most PPI representatives and the trial team.
Discussion
This qualitative pre-trial study was designed to explore
health-care professionals’ perspectives on the design,
relevance and feasibility of delivering and recruiting to
the PrepareME RCT. The findings, supported by obser-
vations of a PAG workshop and introductory site visits,
informed changes to the trial design and protocol.
Findings from the interviews on trial design focused
on logistical issues, particularly concerns about the
ability to deliver home visits as part of the intervention.
Fig. 4 Prepare for Kidney Care: revised trial pathways
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Professionals also discussed issues with the trial inclu-
sion criteria, namely approaching patients for study
participation when their eGFR < 15, as some commen-
ted that patients would have already made treatment
decisions in routine care. The presentation of the RCT
and the trial arms, specifically the name of the trial
(PrepareME) and the intervention (Prepare for conserva-
tive care), were suggested to have negative connotations,
which could impact patients’ interpretations and willing-
ness to participate. Further issues concerned perceived
imbalances in the presentation of the trial pathways, as
interview participants and PAG members highlighted
that patients’ health appeared to decline only in the
Prepare for conservative care pathway (rather than in
both pathways). Factors that were anticipated to hinder
recruitment included expectations that patients would
have treatment preferences and concerns about clinical
professionals’ perceptions of equipoise. Equipoise issues
were indirectly implied through professionals’ comments
on the registry follow-up study, with some staff suggest-
ing that this non-randomised study could provide a
more comfortable substitute for the RCT.
As an outcome of this research, organisational and
design issues were mostly addressed at the trial outset,
for example, updating the protocol to add flexibility to
home visits. Changes were made to the name of the trial
and the conservative care pathway (renamed Prepare for
Kidney Care and Prepare for responsive management,
respectively), and the presentation of the trial arms was
refined to communicate clearly the constituents of each
arm and to convey equipoise. Other issues were more
difficult to address immediately, particularly anticipated
recruitment problems, as it was unclear whether these
issues would occur, and some of these issues were sensi-
tive and complex, apparently related to the personal
views of health-care professionals towards the RCT.
These have been recognised elsewhere as the emotional
and intellectual aspects of trial recruitment [21–24],
including recruiter struggles with equipoise [21–23] and
reluctance to explore patient preferences [22].
A QRI was later integrated into trial recruitment
within Prepare for Kidney Care, with the aim to under-
stand recruitment in depth, as it proceeds, and to iden-
tify factors that are hindering trial uptake [16]. The
findings are used to inform strategies to optimise re-
cruitment, often comprising support and training of re-
cruiters [25]. Recruitment and the QRI are now
underway for Prepare for Kidney Care, and whilst the
QRI aims to identify new recruitment obstacles, issues
highlighted in this pre-trial work have informed some of
the focus of investigation, allowing the team to monitor
these issues and act rapidly if they arise.
The key focus of this study was on the views of
health-care professionals on the proposed RCT. This was
a strength, as staff were able to offer real insights into
problems with integrating the trial into routine practice.
As with many RCTs, patient involvement was—and con-
tinues to be—essential in the Prepare for Kidney Care
s
Fig. 5 Comparison of trial pathways
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study; however, the contributions from staff delivering
existing care included unique (insider) insights into key
organisational issues likely to affect the proposed trial’s
execution. A review of pre-trial work found that most
existing qualitative studies on the acceptability of trial in-
terventions were from the perspective of patients, with
few including professionals [7]. We were able to identify
only one other pre-trial study, the Bluebelle Study [6], that
used interviews with health-care professionals to assess
the feasibility of trial design and recruitment. The inter-
views sought feedback on a proposed trial to compare
types of surgical wound dressings, with findings indicating
that a proposed comparator was not routinely used in
practice, resulting in a change to the trial arms.
Other studies have instead integrated qualitative
methods during recruitment (i.e. the QRI), with most of
these emphasising problems with recruitment practices
rather than design, including logistical issues (e.g.
screening, assessing eligibility and approaching patients)
and the communication of trial information [26–32].
Design issues were identified within only one study (Pro-
tecT—Prostate testing for cancer and treatment) [26],
specifically problems with the non-radical comparator
arm. Like our work, the name of the arm was changed
from ‘watchful waiting’ to ‘active monitoring’ to avoid
non-interventionist connotations, and monitoring visits
and tests were added into the active monitoring arm to
balance the intensity of the intervention against its com-
parators. However, the drawback of exploring the
acceptability of RCT design after recruitment is under-
way is that changes cannot always be made in time to
have a positive impact on recruitment. This was demon-
strated in a study by Ziebland et al. [33], who identified
that the name of a trial (Spine Stabilisation Trial) did
not suggest equivalence between its comparators by
emphasising the surgical over the rehabilitation arm.
The authors suggested that this contributed to recruiter
misunderstandings of the trial design (i.e. not under-
standing that the treatments were equivalent), poten-
tially negatively impacting recruitment discussions and
uptake, and after the trial, affecting clinicians’ ability to
interpret the trial’s results and apply them in practice.
There were several advantages to undertaking this
pre-trial qualitative work in our study. We could address
issues likely to affect recruitment and trial delivery in ad-
vance, which helped to maximise the research value, as
the findings impacted specific trial delivery rather than
generating future lessons [7]. The work supports the
importance of an early investigation to ensure that sites
have the appropriate infrastructure and resources to
support trial delivery and procedures, to mitigate prob-
lems with trial conduct and to avoid delays [34]. We
identified unanticipated resource constraints related to
delivering the home visits in the intervention, suggesting
qualitative pre-trial work to be particularly important
when exploring potential practical and resource-related
obstacles in trials aiming to deliver new interventions in
existing NHS systems. This pre-trial work also allowed
us to strengthen the relevance and acceptability of a new
intervention for comparison (Prepare for responsive man-
agement) by drawing on the views of key staff and patient
stakeholders [7]. Finally, undertaking early qualitative work
can have the added advantage of encouraging improved
collaborations between qualitative researchers and trial
teams, facilitating ongoing work during trial recruitment,
and potentially enhancing the integration and impact of
qualitative research findings on trial conduct [35, 36].
This study has several limitations. We were able to
conduct interviews with health-care professionals in only
four of the six sites. This was due to delays in receiving
local trust approval to begin recruitment at the
remaining sites, which delayed introductory site visits
and the opportunity for staff to hear about the study
before being approached for interview. We allowed 6
months for data collection and analysis prior to recruit-
ment commencing. However, we found that the timeline
for completing the interviews was tight due to delays
involved in gaining site approvals, the difficulties in
obtaining health-care professionals’ time to conduct the
interviews, and the time needed to feed back and imple-
ment the findings prior to recruitment. This meant, for
example, that the findings had to be presented at the
expert consensus meeting before all the interviews were
complete, and not all interview findings could be fed
into the PAG workshop for their reflections. Although
the order in which we could undertake the interviews,
observations and feedback session was restricted by the
availability of the relative participants and stakeholders,
we did ensure that we had complete input from all these
groups before we made changes to the trial design.
Future studies would benefit from ensuring during the
planning stages that they allow enough time and
resources to organise stakeholder input, complete data
collection and implement changes to the trial design
prior to recruitment, including a draft timeline of when
it would be optimal to conduct and present various
aspects of the research with and to the various stake-
holder groups. This may be facilitated by including the
observation of PAG and introductory site meetings as
formal data collection opportunities, allowing time for
formal analyses and the chance also to present data
from these investigations to stakeholders at the expert
consensus meeting.
We did not interview patients to gather their views on
the trial design prior to recruitment, which would have
added empirical evidence of another key stakeholder
group’s perspective. However, the rationale for interview-
ing health-care professionals first and foremost was to
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identify barriers to integrating the RCT into routine
care, which might have prevented the trial running in
participating sites. The views of patient representatives
on trial design were gained through pre-trial workshops,
and insights from the PAG workshop reported in this
paper were considered in relation to the views of health-
care professionals, which helped to support changes to
the trial design. As part of the Prepare for Kidney Care
QRI, interviews are now also underway with patients
who have been approached for participation, for their re-
flections on the trial and recruitment processes. These
interviews aim to explore the reasons behind patients’
participation decisions, highlighting any further design
or recruitment obstacles. Had these patient interviews
taken place at the pre-trial phase, they would have relied
on patients considering participation hypothetically,
which has limitations. We also did pre-trial work with
only the first wave of sites involved in the pilot RCT.
However, the challenges that have emerged from this
pre-trial stage have informed the feasibility question-
naires and discussion points at new site initiation visits,
which are helping the trial team to tease out and explore
solutions to problems with trial conduct in advance.
A final limitation of this work is the inability to evalu-
ate formally the influence of early changes made to the
trial design on RCT delivery and recruitment. This
would have been interesting from a trial methodology
perspective. However, it is unlikely that the changes
would have resulted in a negative impact, as changes
focused on adding balance and flexibility to the design
and delivery of the study arms and were grounded in
data and insights emerging from the concerns of a range
of health-care professionals and PPI representatives [7].
Conclusions
This qualitative study has had important implications for
the Prepare for Kidney Care RCT, identifying challenges
related to its design and recruitment and allowing changes
to be made to the RCT intervention and trial delivery in
advance of the trial commencing. The benefits of carrying
out pre-trial qualitative work is that it can inform specific
changes to a trial design, potentially avoiding future issues
with trial conduct, acceptability and recruitment. This
study has also highlighted the value of conducting pre-
trial work with health-care professionals who are deliver-
ing current clinical care, as they are able to offer key and
knowledgeable insights into the potential barriers to inte-
grating aspects of a trial into routine practice. Considering
the views of health-care professionals in relation to
other more typical non-empirical activities, such as
introductory site visits and PPI activities, can provide
an in-depth and comprehensive overview of issues that
should (and can be) addressed in advance of trial deliv-
ery. We suggest that pre-trial qualitative work should
be more often undertaken in addition to integrated
qualitative research during recruitment to identify,
monitor and address design and recruitment related is-
sues in advance and as they arise.
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